- Home
- AMTB vs RGNX Comparison
AMTB vs RGNX Comparison
Compare AMTB & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMTB | RGNX |
|---|---|---|
| Founded | 1979 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 776.2M | 661.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | AMTB | RGNX |
|---|---|---|
| Price | $20.49 | $13.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $21.75 | ★ $29.00 |
| AVG Volume (30 Days) | 251.0K | ★ 676.4K |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $388,504,000.00 | $161,318,000.00 |
| Revenue This Year | $61.42 | $132.80 |
| Revenue Next Year | $2.10 | $48.47 |
| P/E Ratio | $12.82 | ★ N/A |
| Revenue Growth | 51.98 | ★ 91.30 |
| 52 Week Low | $15.62 | $5.04 |
| 52 Week High | $25.03 | $14.93 |
Technical Indicators
Market Signals| Indicator | AMTB | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 70.85 | 53.88 |
| Support Level | $20.31 | $12.69 |
| Resistance Level | $21.00 | $14.93 |
| Average True Range (ATR) | 0.49 | 0.86 |
| MACD | 0.12 | 0.05 |
| Stochastic Oscillator | 76.96 | 37.80 |
Price Performance
Historical ComparisonAbout AMTB Amerant Bancorp Inc.
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.